Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported FCF Margin of 145.59% for Q1 2026, down 2544.0% year-over-year from 5.96% in Q1 2025, and down 202.48% on a QoQ basis from 48.13% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 11 years of FCF Margin data on file, last reported at 145.59% in Q1 2026.
- Quarterly FCF Margin fell 2544.0% year-over-year to 145.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.96% (down 786.0% YoY) and the FY2025 annual result came in at 69.99%, up 519.0% from the prior year.
- FCF Margin retreated to 145.59% in Q1 2026 per RARE's latest filing, from 48.13% in the prior quarter.
- Across five years, FCF Margin topped out at 40.45% in Q4 2023 and bottomed at 178.02% in Q1 2022.
- The 5-year median for FCF Margin is 85.02% (2022), against an average of 99.13%.
- The widest annual swing landed in 2023, when FCF Margin sank 5528 bps; it then surged 10526 bps in 2024.
- Tracing RARE's FCF Margin over 5 years: stood at 85.02% in 2022, then soared by 52 bps to 40.45% in 2023, then retreated by 19 bps to 48.27% in 2024, then rose by 0 bps to 48.13% in 2025, then tumbled by 202 bps to 145.59% in 2026.
- Per Business Quant, the three latest RARE FCF Margin figures stand at 145.59% (Q1 2026), 48.13% (Q4 2025), and 57.96% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -145.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.59% |
| Dec 31, 2025 | -48.13% |
| Sep 30, 2025 | -57.96% |
| Jun 30, 2025 | -66.99% |
| Mar 31, 2025 | -120.14% |
| Dec 31, 2024 | -48.27% |
| Sep 30, 2024 | -52.28% |
| Jun 30, 2024 | -52.09% |
| Mar 31, 2024 | -176.42% |
| Dec 31, 2023 | -40.45% |
| Sep 30, 2023 | -157.55% |
| Jun 30, 2023 | -104.41% |
| Mar 31, 2023 | -165.18% |
| Dec 31, 2022 | -85.02% |
| Sep 30, 2022 | -102.27% |
| Jun 30, 2022 | -84.50% |
| Mar 31, 2022 | -178.02% |
| Dec 31, 2021 | -84.41% |
| Sep 30, 2021 | -98.24% |
| Jun 30, 2021 | -98.22% |
| Mar 31, 2021 | -176.83% |
| Dec 31, 2020 | -92.20% |
| Sep 30, 2020 | -80.70% |
| Jun 30, 2020 | 134.94% |
| Mar 31, 2020 | -300.88% |
| Dec 31, 2019 | -234.71% |
| Sep 30, 2019 | -362.55% |
| Jun 30, 2019 | -390.50% |
| Mar 31, 2019 | -543.88% |
| Dec 31, 2018 | -350.81% |
| Sep 30, 2018 | -596.69% |
| Jun 30, 2018 | -605.40% |
| Mar 31, 2018 | -842.49% |
| Dec 31, 2017 | -3,825.19% |
| Sep 30, 2017 | -31,831.31% |
| Dec 31, 2016 | -766,100.00% |
| Sep 30, 2016 | -28,600.00% |
| Jun 30, 2016 | -262,935.29% |